08C.386 :    Colorectal

Purpose:  Primary objective: -To demonstrate improvement in overall survival (OS) with aflibercept by comparison to placebo in patients with colorectal cancer treated with FOLFIRI as second line treatment for metastatic disease. Secondary objectives: -To compare progression free survival (PFS) in the 2 treatment arms -To evaluate overall response rate (RR) in the 2 treatment arms -To evaluate the safety profile in the 2 treatment arms -To assess the pharmacokinetics of IV aflibercept -To assess immunogenicity of IV aflibercept

Title:  A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan / 5-FU Combination (FOLFIRI) after failure of an oxaliplatin based regimen (VELOUR)

09C.140 :    Colorectal

Purpose:  To determine the clinical efficacy and toxicity of ABT-869 in combination with mFOLFOX versus bevacizumab and mFOLFOX6 as second-line treatment in subjects with locally recurrent or metastatic colon or rectal cancer

Title:  As Open-Label, Randomized Phase 2 Study of ABT-869 in Combination with mFOLFOX6 (Oxaliplatin, Flurouracil, and Folonic Acid) versus Bevacizumab in Combination with mFOLFOX6 in the Second-line Treatment of Subjects with Advanced Colorectal Cancer.

2 records found.